All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Excerpt
The guideline gives recommendations about the clinical signs, symptoms and types of presentation or conditions that should alert practitioners to consider the presence of coeliac disease, and suggests a scheme of investigation to follow when making the diagnosis. It is expected that implementation of the guideline recommendations will lead to many new cases being diagnosed and much ill health being alleviated.
Contents
- Foreword
- Patient-centred care
- 1. Summary
- 2. Evidence review
- 2.1 Introduction
- 2.2 Prevalence of coeliac disease
- 2.3 The possible long-term consequences of undiagnosed coeliac disease
- 2.4 Signs and symptoms of coeliac disease and coexisting conditions with coeliac disease
- 2.5 Serological tests in the diagnostic process for coeliac disease
- 2.6 Research recommendations
- 3. References, glossary and abbreviations
- 4. Methods
- 5. Contributors
Five NICE guidelines have been included on the Bookshelf as part of a pilot
project. All NICE guidance is available on the NICE website at www
NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.
This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
- Coeliac DiseaseCoeliac Disease
Your browsing activity is empty.
Activity recording is turned off.
See more...